AYTU BIOPHARMA, INC Amortization of Intangible Assets
AYTU BIOPHARMA, INC (AYTU) reported Amortization of Intangible Assets of $2.49 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-09-22
- AYTU BIOPHARMA, INC amortization of intangible assets for the quarter ending 2026-06-30 was $761.00K, a 17.37% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of intangible assets for the quarter ending 2026-03-31 was $761.00K, a 17.28% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of intangible assets for the quarter ending 2025-12-31 was $526.00K, a 42.89% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of intangible assets for the quarter ending 2025-09-30 was $444.00K, a 51.79% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of intangible assets for fiscal 2026 was $2.49M, a 32.34% decline from fiscal 2025.
- AYTU BIOPHARMA, INC amortization of intangible assets for fiscal 2025 was $3.68M, a 0.00% change from fiscal 2024.
- AYTU BIOPHARMA, INC amortization of intangible assets for fiscal 2024 was $3.68M, a 23.08% decline from fiscal 2023.
- AYTU BIOPHARMA, INC amortization of intangible assets for fiscal 2023 was $4.79M, a 18.07% decline from fiscal 2022.
| Period end | Amortization of Intangible Assets 1 month | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $761.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $1.52M derived: sum of 2 quarters · filed 2026-09-22 | $2.05M derived: sum of 3 quarters · filed 2026-09-22 | $2.49M 10-K · filed 2026-09-22 | |||||
| 2026-03-31 | $761.00K 10-Q · filed 2026-05-13 | $1.29M derived: sum of 2 quarters · filed 2026-05-13 | $1.73M 10-Q · filed 2026-05-13 | $2.65M derived: sum of 4 quarters · filed 2026-09-22 | |||||
| 2025-12-31 | $526.00K 10-Q · filed 2026-02-03 | $970.00K 10-Q · filed 2026-02-03 | $1.89M derived: sum of 3 quarters · filed 2026-09-22 | $2.81M derived: sum of 4 quarters · filed 2026-09-22 | |||||
| 2025-09-30 | $444.00K 10-Q · filed 2025-11-13 | $1.36M derived: sum of 2 quarters · filed 2026-09-22 | $2.29M derived: sum of 3 quarters · filed 2026-09-22 | $3.21M derived: sum of 4 quarters · filed 2026-09-22 | |||||
| 2025-06-30 | $921.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $1.84M derived: sum of 2 quarters · filed 2026-09-22 | $2.76M derived: sum of 3 quarters · filed 2026-09-22 | $3.68M 10-K · filed 2026-09-22 | |||||
| 2025-03-31 | $920.00K 10-Q · filed 2026-05-13 | $1.84M derived: sum of 2 quarters · filed 2026-05-13 | $2.76M 10-Q · filed 2026-05-13 | $3.68M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | $921.00K 10-Q · filed 2026-02-03 | $1.84M 10-Q · filed 2026-02-03 | $2.76M derived: sum of 3 quarters · filed 2026-02-03 | $3.68M derived: sum of 4 quarters · filed 2026-02-03 | |||||
| 2024-09-30 | $921.00K 10-Q · filed 2025-11-13 | $1.84M derived: sum of 2 quarters · filed 2025-11-13 | $2.76M derived: sum of 3 quarters · filed 2025-11-13 | $3.68M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $921.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $1.84M derived: sum of 2 quarters · filed 2025-09-23 | $2.76M derived: sum of 3 quarters · filed 2025-09-23 | $3.68M 10-K · filed 2025-09-23 | $5.21M 10-K · filed 2024-09-26 | ||||
| 2024-03-31 | $920.00K 10-Q · filed 2025-05-14 | $1.30M 10-Q · filed 2024-05-15 | $1.84M derived: sum of 2 quarters · filed 2025-05-14 | $2.76M 10-Q · filed 2025-05-14 | $3.91M 10-Q · filed 2024-05-15 | $3.96M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $918.00K 10-Q · filed 2025-02-12 | $1.30M 10-Q · filed 2024-02-14 | $1.84M 10-Q · filed 2025-02-12 | $2.61M 10-Q · filed 2024-02-14 | $3.04M derived: sum of 3 quarters · filed 2025-02-12 | $4.24M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-09-30 | $924.00K 10-Q · filed 2024-11-13 | $1.31M 10-Q · filed 2023-11-14 | $2.12M derived: sum of 2 quarters · filed 2024-11-13 | $3.32M derived: sum of 3 quarters · filed 2024-11-13 | $4.51M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $2.39M derived: sum of 2 quarters · filed 2024-09-26 | $3.59M derived: sum of 3 quarters · filed 2024-09-26 | $4.79M 10-K · filed 2024-09-26 | |||||
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-15 | $2.40M derived: sum of 2 quarters · filed 2024-05-15 | $3.59M 10-Q · filed 2024-05-15 | $4.89M derived: sum of 4 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | $1.20M 10-Q · filed 2024-02-14 | $2.40M 10-Q · filed 2024-02-14 | $3.69M derived: sum of 3 quarters · filed 2024-02-14 | $5.20M derived: sum of 4 quarters · filed 2024-02-14 | |||||
| 2022-09-30 | $1.20M 10-Q · filed 2023-11-14 | $2.50M derived: sum of 2 quarters · filed 2023-11-14 | $4.00M derived: sum of 3 quarters · filed 2023-11-14 | $5.50M derived: sum of 4 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $2.80M derived: sum of 2 quarters · filed 2023-10-12 | $4.31M derived: sum of 3 quarters · filed 2023-10-12 | $5.84M 10-K · filed 2023-10-12 | $4.07M 10-K · filed 2022-09-27 | ||||
| 2022-03-31 | $1.50M 10-Q · filed 2023-05-11 | $1.06M 10-Q · filed 2022-05-16 | $3.01M derived: sum of 2 quarters · filed 2023-05-11 | $4.55M 10-Q · filed 2023-05-11 | $3.21M 10-Q · filed 2022-05-16 | $5.80M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $1.50M 10-Q · filed 2023-02-21 | $1.06M 10-Q · filed 2022-02-14 | $3.04M 10-Q · filed 2023-02-21 | $2.15M 10-Q · filed 2022-02-14 | $4.30M derived: sum of 3 quarters · filed 2023-02-21 | $5.88M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-09-30 | $1.54M 10-Q/A · filed 2023-02-21 | $1.09M 10-Q · filed 2021-11-15 | $2.79M derived: sum of 2 quarters · filed 2023-02-21 | $4.38M derived: sum of 3 quarters · filed 2023-02-21 | $5.96M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $2.84M derived: sum of 2 quarters · filed 2022-09-27 | $4.42M derived: sum of 3 quarters · filed 2022-09-27 | $6.01M 10-K · filed 2022-09-27 | |||||
| 2021-03-31 | $1.58M 10-Q · filed 2022-05-16 | $1.70M 10-Q · filed 2021-05-17 | $3.17M derived: sum of 2 quarters · filed 2022-05-16 | $4.75M 10-Q · filed 2022-05-16 | $4.90M 10-Q · filed 2021-05-17 | $6.34M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $1.58M 10-Q · filed 2022-02-14 | $1.58M 10-Q · filed 2021-02-11 | $3.17M 10-Q · filed 2022-02-14 | $3.17M 10-Q · filed 2021-02-11 | $4.76M derived: sum of 3 quarters · filed 2022-02-14 | $6.16M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $1.58M 10-Q · filed 2021-11-15 | $1.58M 10-Q · filed 2020-11-12 | $3.17M derived: sum of 2 quarters · filed 2021-11-15 | $4.58M derived: sum of 3 quarters · filed 2021-11-15 | $5.53M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $2.99M derived: sum of 2 quarters · filed 2021-09-28 | $3.94M derived: sum of 3 quarters · filed 2021-09-28 | $4.49M 10-K · filed 2021-09-28 | $4.49M 10-K · filed 2020-10-06 | ||||
| 2020-03-31 | $1.40M 10-Q · filed 2021-05-17 | $1.37M 10-Q · filed 2020-05-15 | $2.35M derived: sum of 2 quarters · filed 2021-05-17 | $2.90M 10-Q · filed 2021-05-17 | $2.90M 10-Q · filed 2020-05-15 | $3.50M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $953.45K 10-Q · filed 2021-02-11 | $1.53M 10-Q · filed 2021-02-11 | $2.10M derived: sum of 3 quarters · filed 2021-02-11 | $2.68M derived: sum of 4 quarters · filed 2021-02-11 | |||||
| 2019-09-30 | $575.12K 10-Q · filed 2020-11-12 | $1.15M derived: sum of 2 quarters · filed 2020-11-12 | $1.73M derived: sum of 3 quarters · filed 2020-11-12 | $2.26M derived: sum of 4 quarters · filed 2020-11-12 | |||||
| 2019-06-30 | $575.12K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $1.15M derived: sum of 2 quarters · filed 2020-10-06 | $1.68M derived: sum of 3 quarters · filed 2020-10-06 | $2.14M 10-K · filed 2020-10-06 | |||||
| 2019-03-31 | $575.12K 10-Q · filed 2020-05-15 | $1.11M derived: sum of 2 quarters · filed 2020-05-15 | $1.56M 10-Q · filed 2020-05-15 | $1.96M derived: sum of 4 quarters · filed 2020-05-15 | |||||
| 2018-12-31 | $534.06K 10-Q · filed 2020-02-14 | $986.02K 10-Q · filed 2020-02-14 | $1.38M derived: sum of 3 quarters · filed 2020-02-14 | $1.77M derived: sum of 4 quarters · filed 2020-02-14 | |||||
| 2018-09-30 | $451.96K 10-Q · filed 2019-11-14 | $849.40K derived: sum of 2 quarters · filed 2019-11-14 | $1.24M derived: sum of 3 quarters · filed 2019-11-14 | $1.62M derived: sum of 4 quarters · filed 2019-11-14 | |||||
| 2018-06-30 | $397.45K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $785.05K derived: sum of 2 quarters · filed 2019-09-26 | $1.17M derived: sum of 3 quarters · filed 2019-09-26 | $1.55M 10-K · filed 2019-09-26 | |||||
| 2018-03-31 | $387.61K 10-Q · filed 2019-05-14 | $771.42K derived: sum of 2 quarters · filed 2019-05-14 | $1.16M 10-Q · filed 2019-05-14 | $1.16M 10-Q · filed 2018-05-14 | $1.55M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $383.81K 10-Q · filed 2019-05-14 | $769.65K 10-Q · filed 2019-05-14 | $1.17M derived: sum of 3 quarters · filed 2019-05-14 | $1.60M derived: sum of 4 quarters · filed 2019-05-14 | |||||
| 2017-09-30 | $385.84K 10-Q · filed 2018-11-07 | $783.57K derived: sum of 2 quarters · filed 2018-11-07 | $1.22M derived: sum of 3 quarters · filed 2018-11-07 | $1.66M derived: sum of 4 quarters · filed 2018-11-07 | |||||
| 2017-06-30 | $397.73K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $834.74K derived: sum of 2 quarters · filed 2018-09-06 | $1.27M derived: sum of 3 quarters · filed 2018-09-06 | $1.71M 10-K · filed 2018-09-06 | |||||
| 2017-03-31 | $437.01K 10-Q · filed 2018-05-14 | $874.03K derived: sum of 2 quarters · filed 2018-05-14 | $1.31M 10-Q · filed 2018-05-14 | $1.69M derived: sum of 4 quarters · filed 2018-05-14 | |||||
| 2016-12-31 | $437.01K 10-Q · filed 2017-02-09 | $874.03K 10-Q · filed 2017-02-09 | $1.25M derived: sum of 3 quarters · filed 2017-08-31 | $1.37M derived: sum of 4 quarters · filed 2017-08-31 | |||||
| 2016-09-30 | $437.01K 10-Q · filed 2016-11-07 | $817.09K derived: sum of 2 quarters · filed 2017-08-31 | $935.78K derived: sum of 3 quarters · filed 2017-08-31 | $1.04M derived: sum of 4 quarters · filed 2017-08-31 | |||||
| 2016-06-30 | $380.07K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $498.77K derived: sum of 2 quarters · filed 2017-08-31 | $607.26K derived: sum of 3 quarters · filed 2017-08-31 | $664.71K 10-K · filed 2017-08-31 | |||||
| 2016-03-31 | $118.70K 10-Q · filed 2017-05-11 | $227.19K derived: sum of 2 quarters · filed 2017-05-11 | $284.63K 10-Q · filed 2017-05-11 | ||||||
| 2015-12-31 | $108.49K 10-Q · filed 2017-02-09 | $165.94K 10-Q · filed 2017-02-09 | |||||||
| 2015-10-05 | $174.00K 10-K · filed 2016-09-01 | ||||||||
| 2015-09-30 | $57.45K 10-Q · filed 2016-11-07 | ||||||||
| 2015-06-30 | $90.66K 10-K · filed 2016-09-01 | $71.00K 10-K · filed 2015-09-28 | |||||||
| 2014-06-30 | $70.00K 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |